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Abstract. 
Objective: In general, the typical outcome of patients with locally advanced esophageal 
squamous cell carcinoma is poor. Recently, attempts have been made to improve survival of 
patients with esophageal cancer using preoperative chemoradiotherapy followed by surgery. 
The experience of a single center in Southern Taiwan with esophageal squamous cell carci-
noma was reviewed to determine which clinicopathologic variables could predict survival. 
Methods: One hundred and one patients with diagnosed esophageal squamous cell carcinoma 
who were treated with preoperative chemoradiotherapy followed by surgery at Kaohsiung 
Chang Gung Memorial Hospital were retrospectively reviewed. Univariate and multivariate 
survival analyses were performed using log-rank and Cox proportional hazards models. 
Results: Of these 101 patients, 26% (26 of 101) achieved a pathologic complete response to 
treatment. Univariate analysis revealed that clinical T4 disease and absence of pathologic 
complete response were significantly associated with worse overall survival and disease-free 
survival. The 3-year overall survival rates were 50% and 24% in patients with clinical T1~3 
and T4 disease, respectively (P = 0.01).The 3-year overall survival rates were 68% and 28% in 
patients with and without pathologic complete response, respectively (P = 0.001). Multivariate 
analysis also showed that clinical T4 disease and absence of pathologic complete response 
were independently associated with inferior overall and disease-free survival. 
Conclusions: Clinical T4 disease and absence of pathologic complete response were associ-
ated with significantly worse survival in patients with esophageal squamous cell carcinoma 
receiving preoperative chemoradiotherapy followed by surgery. 
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中文摘要 
目的：局部晚期食道鱗狀上皮細胞癌病患的治療結果極差。近年來，術前化學放射治療
合併手術常被用來試著改善此類病人預後,，我們回溯高雄長庚醫院使用術前化學放射治
療合併手術治療局部晚期食道鱗狀上皮細胞癌病患的臨床經驗並試圖找出可預測病人存
活的臨床病理因子。 
方法：我們總共回溯了 101 位在高雄長庚診斷食道鱗狀上皮細胞癌病患並接受術前化學
放射治療合併手術。單變量存活分析及多變量存活分析分別是使用對數等級檢定(log-rank 
test)及 Cox 比例風險模型。 
結果：在 101 位病人中，有 26 位（26%）達到病理完全反應，單變量存活分析顯示臨床
T4 分期及無法達到病理完全反應的病人有較差的整體存活率及無病存活率。三年整體存
活率在臨床 T1~3 分期及臨床 T4 分期的病人分別是 50%及 24% (P= 0.01)。三年整體存活
率在有達到病理完全反應的病人及無法達到病理完全反應的病人分別是 68%及 28% (P= 
0.001)。多變量存活分析也發現臨床 T4 分期以及無法達到病理完全反應為較差的整體存
活率及無病存活率的獨立預後因子。 
結論：臨床 T4 分期及無法達到病理完全反應明顯地與局部晚期食道鱗狀上皮細胞癌病患
接受術前化學放射治療合併手術後較差的預後相關。 
 
關鍵字: 食道癌、鱗狀上皮細胞癌、術前化學放射治療合併手術、食道切除手術、
病理完全反應 
 
INTRODUCTION 
Esophageal cancer is the sixth-most common 
cause of cancer death among men in Asian countries. 
The major histological types of esophageal cancer are 
adenocarcinoma and squamous cell carcinoma. Alt-
hough adenocarcinomas are more prevalent in the 
United states [1], ninety percent of all esophageal 
cancer in Asian men is esophageal squamous cell car-
cinoma, which contrasts with those percentages found 
in men from western countries [2]. Previous studies 
[3,4] reported that these two histological tumor types 
of esophageal cancer exhibit different behavior, and 
should be analyzed separately.  
The majority of patients with esophageal squa-
mous cell carcinoma have locally advanced disease 
when diagnosed. Esophagectomy combined with 
lymph node dissection is the main treatment for 
esophageal squamous cell carcinoma. However, the 
outcome of patients with locally advanced esophageal 
squamous cell carcinoma treated with surgery alone is 
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unsatisfactory, with 5-year survival rate of less than 
30% [5-8]. In an attempt to improve these survival 
rates, a multimodality approach, preoperative chemo-
radiotherapy followed by surgery, has been advocated 
to downstage the primary tumor, thus increasing re-
sectability rates and eliminating micrometastases 
[9,10]. The first randomized controlled trial of patients 
with esophageal cancer treated with preoperative 
chemoradiotherapy was reported in 1992 by Nygaard 
et al. [11], and revealed that preoperative chemother-
apy and radiotherapy prolonged patient survival. Since 
then, several studies [6,7,12] comparing preoperative 
chemoradiotherapy followed by surgery with surgery 
alone have showed a survival benefit for preoperative 
chemoradiotherapy, whereas others have not found 
any survival benefit by preoperative chemoradiother-
apy versus surgery alone [8,13-16]. Most randomized 
controlled studies of preoperative chemoradiotherapy 
versus surgery alone do not have enough power to 
show smaller yet worthwhile survival improvements, 
particularly if tumors are divided into histological 
subtypes of squamous cell carcinoma and adenocar-
cinoma. Therefore, Gebski et al. conducted a meta- 
analysis and reported that a significant survival benefit 
was evident for preoperative chemoradiotherapy in 
patients with esophageal squamous cell carcinoma 
[17]. Thus, preoperative chemoradiotherapy followed 
by surgery was gradually applied to clinical practice in 
our hospital for patients with locally advanced esoph-
ageal squamous cell carcinoma. Many of the above- 
mentioned trials have identified several factors that 
may contribute to improved survival in patients un-
dergoing preoperative chemoradiotherapy followed by 
surgery, but little is known as to their application for 
patients in Southern Taiwan. The aim of the present 
study was to retrospectively review our experience 
with 101 esophageal squamous cell carcinoma patients 
undergoing preoperative chemoradiotherapy followed 
by surgery and attempt to determine which factors 
may contribute to improvements in overall survival 
and disease-free survival. 
 
MATERIALS AND METHODS 
 
Patient Population 
Patients with esophageal squamous cell carcinoma 
who were treated with preoperative chemoradiothera-
py followed by surgery from 2000 to 2012 at 
Kaohsiung Chang Gung Memorial Hospital were ret-
rospectively reviewed. Patients with synchronous 
cancers were excluded. This study was approved by 
the institutional review board of Chang Gung Memo-
rial Hospital.  
In the present study, 101 patients with esophageal 
squamous cell carcinoma who were treated with pre-
operative chemoradiotherapy followed by surgery 
were identified. Among these 101 patients, 26 (26%) 
achieved pathologic complete response. Patients were 
evaluated by a multidisciplinary team including a tho-
racic surgeon, a medical oncologist, a radiation on-
cologist, a radiologist and a gastroenterologist. Pre-
treatment staging evaluation included physical and 
endoscopic examinations, contrast-enhanced comput-
ed tomography (CT) scans from the neck to upper 
abdomen, and/or endoscopic ultrasound (EUS). The 
tumor node metastasis stages (TNM) were determined 
according to the 7th American Joint Committee on 
Cancer (AJCC) staging system [18]. 
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Table 1. Clinicopathologic features of 101 patients with esophageal squamous cell carcinoma receiving 
neoadjuvant chemoradiotherapy followed by surgery 
Parameters No. of cases (percentage) 
Age (years)(mean: 52.87 , median: 52 , range: 44 (33-77) )   
＜50  41 (40%) 
50≦ Age＜60 35 (35%) 
60≦ Age＜70 20 (20%) 
70≦ Age 5 (5.0%) 
Sex  
Male 99 (98%) 
Female 2 (2%) 
Clinical 7th AJCC stage   
II 19 (19%) 
III 82 (81%) 
Clinical T stage  
T1 0 
T2 2 (2%) 
T3 52 (52%) 
T4 47 (46%) 
Clinical N stage    
N0 20 (20%) 
N1 41 (40%) 
N2 30 (30%) 
N3 10 (10%) 
Pathologic 7th AJCC stage  
Complete response 26 (26%) 
I  8 (8%) 
II 41 (40%) 
III 24 (24%) 
IV 2 (2%) 
Pathologic T stage    
T0 29 (29%) 
T1 11 (11%) 
T2 22 (22%) 
T3 27 (26%) 
T4 12 (12%) 
Pathologic N stage    
N0 70 (69%) 
N1 27 (27%) 
N2 3 (3%) 
N3 1 (1%) 
Tumor grade    
1 24 (24%) 
2 55 (54%) 
3 22 (22%) 
Primary tumor location    
Upper 20 (20%) 
Middle 43 (42%) 
Lower   38 (38%) 
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Treatment Plan 
Patients were concurrently treated with two cycles 
of cisplatin and 5-fluorouracil-based chemotherapy 
and radiotherapy (36 Gy in 20 fractions). Each cycle 
lasted between 3 and 4 weeks. Radiotherapy was de-
livered in five daily fractions per week of 1.8 Gy dur-
ing the 4 weeks, and three-dimensional conformal 
radiotherapy (CRT) via a four-field technique was 
used for most of the patients. The gross tumor volume 
(GTV) was defined as the gross tumor and lymph 
nodes on the simulation CT scan. The clinical target 
volume (CTV) covered the GTV with a 3-cm cranio-
caudal margin and a 1-cm radial margin and also the 
entire mediastinal lymph nodes. For the upper or low-
er third primaries, bilateral supraclavicular lymph 
nodes or celiac lymph nodes were also included for 
prophylactic irradiation. The planning target volume 
was generated from the CTV with a 1-cm expansion 
in all directions. The radiotherapy was delivered by 
LINAC using 6- or 15-MV photons with 1.8 Gy per 
daily fraction, five fractions per week for a total dose 
of 36 Gy/20 fractions. After 2009, however, we modi-
fied the radiation dose to 50.4 Gy/ 28 fractions. With-
in 3-4 weeks following the end of irradiation, CT 
scans and endoscope were performed to assess the 
treatment response. Then, the multidisciplinary team 
reviewed the clinical information to determine if the 
lesions were resectable. If lesions were classified as 
resec table, surgery was advised 4-6 weeks after the 
end of preoperative chemoradiotherapy. Patients re- 
Table 2. Associations between pathologic complete response and clinicopathologic factors in 101 patients with 
esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy followed by surgery 
Parameters 
Pathologic complete response 
Present  Absent  P value  
Age 
  
  
    
≦52 y/o 11 42 0.23 
＞52 y/o 15 33  
Clinical 7
th
 AJCC stage   
  
  
    
II 6 20 0.42 
III 20 63  
Clinical T stage   
  
  
    
T1+2+3 16 38 0.34 
T4 10 37  
Clinical N stage   
  
  
    
N0 7 13 0.29 
N1+2+3 19 62  
Tumor grade   
  
  
    
1 9 15 0.13 
2+3 17 60  
Primary tumor location  
  
  
    
U 4 16 0.51 
M+L 22 59  
CRT, chemoradiotherapy; *Statistically significant. х2 test or Fisher’s exact test was used for statistical analysis 
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Figure 1. Overall survival (A) and disease-free survival (B) in 101 patients with esophageal squamous cell 
carcinoma receiving preoperative chemoradiotherapy followed by surgery 
 
 
ceiving surgery underwent a radical esophagectomy 
by video-assisted thoracoscopic surgery with cervical 
esophagogastrostomy or an Ivor Lewis esophagecto-
my with intrathoracic anastomosis, two-field lym-
phadenectomy and reconstruction of the digestive tract 
with gastric tube. Pathologic complete response was 
defined as the complete disappearance of all viable 
cancer cells in all surgical specimens, including the 
primary esophageal tumor and lymph nodes. 
 
Follow Up 
After the operation, patients were scheduled for 
follow-ups at 3-month intervals in years 1 and 2, 
6-month intervals in years 3 to 5, and annually there-
after. Overall survival (OS) was calculated from the 
date of diagnosis to death as a result of all causes. 
Disease-free survival (DFS) was computed from the 
time of surgery to the recurrence or death from any 
cause without evidence of recurrence. 
 
Statistical Analysis 
Statistical analysis was performed with the Statis-
tical Package for the Social Sciences (SPSS, ver. 13.0, 
Chicago, IL, USA), and the χ2 test or Fisher’s exact 
test were used to compare data between the two 
groups. For survival analysis, the Kaplan-Meier 
method was used for univariate analysis, and the dif-
ference between survival curves was tested by a 
log-rank test. In a stepwise forward fashion, parame-
ters with P < 0.1 at the univariate level were in princi-
ple entered into a Cox regression model to analyze 
their relative prognostic importance. However, as 
component factors of the 7th AJCC staging system, 
the 7th T stage and 7th N stage were not introduced in 
multivariate analyses simultaneously. For all analyses, 
two-sided tests of significance were used with P < 
0.05 considered to be significant.  
 
RESULTS 
 
Patient Characteristics 
A total of 101 patients were included in the study 
with a median age of 52 years (range, 33-77 years). 
Among them, 99 were men and 2 were women. The 
pretreatment analyses of the clinical tumor stage re-
vealed T2 in 2 patients (2%), T3 in 52 patients (52%), 
and T4 in 47 patients (46%). Additional pretreatment 
analyses according to the AJCC staging system 
demonstrated clinical stage II tumors for 19 patients 
(19%) and clinical stage III for 82 patients (81%).  
A  B 
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Figure 2. Overall survival (A) and disease-free survival (B) according to pretreatment clinical T stage 
 
 
Further analyses of histological grades showed a grade 
1 lesion in 24 patients, grade 2 in 55 patients, and 
grade 3 in 22 patients. Primary tumor location was 
found to be upper in 20 patients (20%), middle in 43 
patients (43%), and lower in 38 patients (38%). 
Among these 101 patients, 26 achieved pathologic 
complete response after preoperative chemoradio-
therapy (Table 1). The 3-year OS and DFS of these 
101 patients were 38.0% and 34.3% (Figure 1, A and 
B), respectively. The median periods of follow-up 
were 64 months (range, 18.0-103.5 months) for the 33 
survivors and 21.0 months (range, 3.8-103.5 months) 
for all 101 patients. 
 
Correlation between Clinicopathologic 
Parameters and Pathologic Complete 
Response 
We did not observe significant correlation between 
pathologic complete response with age, clinical AJCC 
stage, clinical T stage, clinical N stage, tumor grade, 
and primary tumor location (Table 2). 
 
Survival Analyses of all 101 Patients 
Univariate analyses demonstrated that clinical T 
stage (3-year OS rate, 50% vs 24% , P =0.01; 3-year 
DFS rate, 45% vs 22% , P = 0.006; Figure 2, A and B), 
and pathologic complete response (3-year OS rate, 
28% vs 68% , P= 0.001; 3-year DFS rate, 23% vs 68 
% , P < 0.001) were associated with the inferior OS 
and DFS (Table 3). But, we did not observe signifi-
cant correlation between OS and DFS with age, clini-
cal N stage, tumor grade, and primary tumor location 
(Table 3). In multivariate analysis, clinical T stage 
was an independent prognosticator for overall survival 
(P = 0.012, odds ratio: 1.854, 95% confidence interval: 
1.146-3.000) and disease-free survival (P = 0.008, 
odds ratio: 1.94, 95% confidence interval: 1.192- 
3.158). Pathologic complete response was also an in-
dependent prognosticator for overall survival (P = 
0.001, odds ratio: 3.169, 95% confidence interval: 
1.567-6.412; Figure 3A) and disease-free survival (P = 
0.001, odds ratio: 3.326, 95% confidence interval: 
1.643- 6.734; Figure 3B). 
 
Survival Analyses of 74 Patients who did 
not Reach Pathologic Complete Response 
We also performed subgroup survival analysis on 
74 patients who did not reach pathologic complete 
response. Univariate analysis demonstrated that clini-
cal T stage (3-year OS rate, 42 % vs 14%, P = 0.004;  
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3-year DFS rate, 36% vs 10%, P = 0.003), pathologic 
AJCC stage (3-year OS rate, 35 % vs 15%, P =0.015; 
3-year DFS rate,  31% vs 6%, P = 0.001) and patho-
logic T stage (3-year OS rate, 44% vs 15%, P = 0.000; 
3-year DFS rate, 38% vs 10%, P = 0.000) were asso-
ciated with inferior OS and DFS. The univariate anal-
ysis are summarized in Table 4. In multivariate analy-
sis, clinical T stage was an independent prognosticator 
for overall survival (P = 0.015, odds ratio: 1.885, 95% 
confidence interval: 1.133-3.137) and disease-free 
survival (P = 0.011, odds ratio: 1.971, 95% confidence 
interval: 1.171-3.315). Pathologic T stage was also an 
independent prognosticator for overall survival (P = 
0.001, odds ratio: 2.655, 95% confidence interval:  
Table 3. Results of univariate log-rank analysis of prognostic factors for overall survival and disease-free 
survival in 101 patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradio-
therapy followed by surgery 
Factors  No. of patients Overall survival (OS) Disease-free survival (DFS) 
3-year OS rate (%) P value 3-year DFS rate (%) P value
Age      
<52 y/o 53 35% 0.59 30% 0.62 
≧52 y/o 48 42%  38%  
Clinical 7th AJCC stage       
II 19 58% 0.16 52% 0.12 
III 82 33%  30%  
Clinical T stage      
T1+2+3 54 50% 0.01* 45% 0.006*
T4 47 24%  22%  
Clinical N stage       
N0 20 50% 0.50 44% 0.37 
N1+2+3 81 35%  32%  
Tumor grade       
1 24 32% 0.65 32% 0.48 
2+3 77 40%  35%  
Primary tumor location       
Upper 20 41% 0.40 23% 0.48 
Middle/Lower 81 25%  37%  
Pathologic CR       
Absent 75 28% 0.001* 23% 0.000*
Present 26 68%  68%  
CR, complete response; *Statistically significant   
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Figure 3. Overall survival (A) and disease-free survival (B) according to the response of preoperative 
chemoradiotherapy 
 
 
1.532-4.600) and disease-free survival (P = 0.000, 
odds ratio: 2.711, 95% confidence interval: 1.563- 
4.703). 
 
DISCUSSION 
Esophageal squamous cell carcinoma is usually 
diagnosed at an advanced stage [19,20]. The outcome 
of patients with locally advanced esophageal squa-
mous cell carcinoma treated with surgery alone is un-
satisfactory, despite recent improvements in technique 
and perioperative management of patients [5]. In an 
attempt to improve survival rates, multimodality ap-
proaches such as preoperative chemoradiotherapy fol-
lowed by surgery have been advocated to treat locally 
advanced esophageal squamous cell carcinoma [9,10, 
17]. Previous series reported that the 3-year OS in 
patients with esophageal squamous cell carcinoma 
receiving preoperative chemoradiotherapy followed 
by surgery ranged from 26 to 39% [8,21]. In our series, 
the 3-year OS was 38%, which is similar to the sur-
vival rate observed in the previous report. 
After preoperative chemoradiotherapy, previous 
studies showed that pathologic complete response can 
be found in 20-40% of resected esophageal tumor 
specimens. There have been indications of a notewor-
thy therapeutic long-term benefit to achieving a path-
ologic complete response. Multiple retrospective se-
ries have reported 5-year survivals of 40-60% in those 
groups of patients when compared with those with 
specimens containing residual disease [22-25]. In our 
series, pathologic complete response was found in 
27% of patients, and the 3-year overall survivals were 
68% and 28% in patients with and without pathologic 
complete response, respectively (P =0.001); these re-
sults further support the previous findings. On the 
other hand, with the development of chemoradiother-
apy, a surrogate marker of treatment efficacy becomes 
important. If tumors can be sterilized after chemoradi-
otherapy, surgery may not be necessary as it can lead 
to additional postoperative mortality and morbidity 
[26]. Otherwise, surgery is strongly suggested to 
eradicate local-regionally residual disease or may be 
taken into consideration as first treatment modality if 
the tumor is resectable. Therefore, there is an urgent 
need to identify patients who are likely or unlikely to 
respond to chemoradiotherapy. If we can find factors 
that predict the effect of chemoradiotherapy, a more 
effective therapeutic strategy can be expected. 
A  B 
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Table 4. Results of univariate log-rank analysis of prognostic factors for overall survival and disease-free 
survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy 
followed by surgery which did NOT achieve pathologic complete response 
Factors  No. of patients Overall survival (OS) Disease-free survival (DFS) 
3-year OS rate (%) P value 3-year DFS rate (%) P value
Age      
<median 52 y/o 42 24% 0.31 18% 0.37 
≧median 52 y/o 33 33%  29%  
Clinical 7th AJCC stage       
II 12 42% 0.40 30% 0.36 
III 63 26%  22%  
Clinical T classification       
T1+2+3 38 42% 0.004* 36% 0.003*
T4 37 14%  10%  
Clinical N status       
N0 13 39% 0.50 27% 0.36 
N1+2+3 62 26%  23%  
Pathological 7th AJCC stage      
I+II 49 35% 0.015* 31% 0.001*
III+IV 26 15%  6%  
Pathological T classification      
T0+1+2 36 44% 0.000* 38% 0.000*
T3+4 39 15%  10%  
Pathological N status       
N0 44 32% 0.72 29% 0.57 
N1+2+3 31 23%  15%  
Tumor grade       
1 15 20% 0.48 20% 0.55 
2+3 60 31%  24%  
Primary tumor location       
Upper 16 19% 0.51 16% 0.71 
Middle/Lower 59 31%  25%  
CR, complete response; *Statistically significant   
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In our series, pretreatment clinical T4 disease was 
an independent prognosticator for overall survival and 
disease-free survival in all 101 patients. For 75 pa-
tients who did not achieve pathologic complete re-
sponse, pretreatment clinical T4 disease and patho-
logic T3~4 disease were also an independent prognos-
ticators for overall survival and disease-free survival. 
Kim et al. [27] and Chao et al. [28] also reported that 
pretreatment clinical stage is an important prognostic 
marker for survival, even though patients achieved 
major response after preoperative chemoradiotherapy. 
These results suggest that adjuvant chemotherapy after 
esophagectomy may be considered in these group of 
patients. 
In conclusion, clinical T4 disease and the absence 
of pathologic complete response were associated with 
significantly worse survival in patients with esopha-
geal squamous cell carcinoma receiving preoperative 
chemoradiotherapy followed by surgery in this retro-
spective analysis. Future studies should focus on the 
role of modalities in restaging after preoperative 
chemoradiotherapy to determine which patients will 
benefit from further esophagectomy. Additionally, it 
is important to further explore the biologic differences 
between patients with and without pathologic com-
plete response. 
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